| # | Title | Journal | Year | Citations |
|---|
| 1 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update | Hepatology International | 2016 | 1,908 |
| 2 | Asia–Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update | Hepatology International | 2017 | 1,537 |
| 3 | Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma | Hepatology International | 2010 | 944 |
| 4 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Hepatology International | 2012 | 874 |
| 5 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL) 2014 | Hepatology International | 2014 | 861 |
| 6 | Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2008 update | Hepatology International | 2008 | 832 |
| 7 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific Association for the study of the liver (APASL) | Hepatology International | 2009 | 709 |
| 8 | Acute-on-chronic liver failure: consensus recommendations of the Asian Pacific association for the study of the liver (APASL): an update | Hepatology International | 2019 | 483 |
| 9 | The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease | Hepatology International | 2020 | 422 |
| 10 | Goals and targets for personalized therapy for HCC | Hepatology International | 2019 | 358 |
| 11 | Role of free radicals in liver diseases | Hepatology International | 2009 | 304 |
| 12 | The role of lipopolysaccharide/toll-like receptor 4 signaling in chronic liver diseases | Hepatology International | 2010 | 253 |
| 13 | The influence of hepatitis B virus genotype and subgenotype on the natural history of chronic hepatitis B | Hepatology International | 2009 | 220 |
| 14 | Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study) | Hepatology International | 2020 | 210 |
| 15 | CSH guidelines for the diagnosis and treatment of drug-induced liver injury | Hepatology International | 2017 | 206 |
| 16 | APASL consensus statements and recommendation on treatment of hepatitis C | Hepatology International | 2016 | 189 |
| 17 | Asian-Pacific Association for the Study of the Liver (APASL) consensus guidelines on invasive and non-invasive assessment of hepatic fibrosis: a 2016 update | Hepatology International | 2017 | 178 |
| 18 | Cirrhotic cardiomyopathy | Hepatology International | 2009 | 172 |
| 19 | Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease | Hepatology International | 2010 | 172 |
| 20 | Updates in the pathogenesis, diagnosis and management of ectopic varices | Hepatology International | 2008 | 159 |
| 21 | Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic review | Hepatology International | 2008 | 156 |
| 22 | APASL consensus statements and management algorithms for hepatitis C virus infection | Hepatology International | 2012 | 152 |
| 23 | Immune and inflammatory pathways in NASH | Hepatology International | 2013 | 151 |
| 24 | Noncirrhotic portal fibrosis/idiopathic portal hypertension: APASL recommendations for diagnosis and treatment | Hepatology International | 2007 | 149 |
| 25 | Gut–liver axis, cirrhosis and portal hypertension: the chicken and the egg | Hepatology International | 2018 | 149 |
| 26 | Liver failure determines the outcome in patients of acute-on-chronic liver failure (ACLF): comparison of APASL ACLF research consortium (AARC) and CLIF-SOFA models | Hepatology International | 2017 | 144 |
| 27 | Myosteatosis and sarcopenia are associated with hepatic encephalopathy in patients with cirrhosis | Hepatology International | 2018 | 143 |
| 28 | Albumin in chronic liver disease: structure, functions and therapeutic implications | Hepatology International | 2016 | 137 |
| 29 | How does hepatic lipid accumulation lead to lipotoxicity in non-alcoholic fatty liver disease? | Hepatology International | 2021 | 137 |
| 30 | Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients | Hepatology International | 2013 | 136 |
| 31 | Hepatic encephalopathy: a critical current review | Hepatology International | 2018 | 132 |
| 32 | Hepatitis C virus as a systemic disease: reaching beyond the liver | Hepatology International | 2016 | 131 |
| 33 | HBeAg seroconversion as an important end point in the treatment of chronic hepatitis B | Hepatology International | 2009 | 128 |
| 34 | Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis | Hepatology International | 2016 | 127 |
| 35 | Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure | Hepatology International | 2008 | 126 |
| 36 | Liver transplantation for acute-on-chronic liver failure | Hepatology International | 2009 | 114 |
| 37 | Diagnosis and management of acute variceal bleeding: Asian Pacific Association for Study of the Liver recommendations | Hepatology International | 2011 | 110 |
| 38 | Coronavirus disease (COVID-19) and the liver: a comprehensive systematic review and meta-analysis | Hepatology International | 2020 | 109 |
| 39 | Assessing liver tumor stiffness by transient elastography | Hepatology International | 2007 | 107 |
| 40 | Clinical significance of serum autoantibodies in patients with NAFLD: results from the nonalcoholic steatohepatitis clinical research network | Hepatology International | 2012 | 106 |
| 41 | Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients | Hepatology International | 2013 | 104 |
| 42 | Hepatitis B reactivation after chemotherapy: two decades of clinical research | Hepatology International | 2008 | 103 |
| 43 | Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management | Hepatology International | 2010 | 103 |
| 44 | Non-invasive diagnosis of hepatic steatosis | Hepatology International | 2017 | 101 |
| 45 | Radiomics in hepatocellular carcinoma: a quantitative review | Hepatology International | 2019 | 100 |
| 46 | New antiviral therapies for chronic hepatitis C | Hepatology International | 2010 | 99 |
| 47 | HBV life cycle and novel drug targets | Hepatology International | 2011 | 97 |
| 48 | Prevalence of chronic liver disease in patients with COVID-19 and their clinical outcomes: a systematic review and meta-analysis | Hepatology International | 2020 | 97 |
| 49 | Natural course following the onset of cirrhosis in patients with chronic hepatitis B: a long-term follow-up study | Hepatology International | 2007 | 96 |
| 50 | Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease | Hepatology International | 2007 | 96 |
